Exhibit 10.24


 


Confidential treatment has been requested
with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.


 


Amendment


 


To the existing Distribution Agreement
signed 15th of December 2014


 


between


 


CytoSorbents Europe GmbH, a corporation having
its offices at Müggelseedamm 131, 12587 Berlin, Germany, existing under the laws of Germany (hereinafter referred to as "CytoSorbents")


 


and


 


Aferetica s.r.l., a corporation having its
offices at Via Spartaco 10, 40138 Bologna, Italy , existing under the laws of Italy, (hereinafter referred to as "Distributor").


 


All terms and conditions of this Distribution
Agreement signed 15th of December 2015 shall remain in force except as amended here:


 




     


     


    

  





CytoSorbentsExclusive Distribution Agreement




 


Confidential treatment has been requested
with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.


 


The following points
of the existing contract will be changed:


 


		9.1	Distributor shall purchase a sufficient amount of Products from the Company so as to meet or exceed
the minimum purchase requirements set forth below.



 


	Calendar year	 	Minimum Purchase Requirements 
	 	 	 
	2017	 	[***] adsorber
	 	 	 
	2018	 	[***] adsorber
	 	 	 
	2019	 	[***] adsorber
	 	 	 
	2020	 	[***] adsorber
	 	 	 
	2021	 	[***] adsorber


 


Distributor strives
to place roughly equal purchase orders per quarter over the year.


 


		20.	Term and Termination



 


		20.1	The term of this Agreement shall begin on the 01st of March 2017 (such date being referred
to as the "Effective Date"). The term of this Agreement shall expire on 31st of December 2021, unless terminated
earlier pursuant to the provisions of this Section. The term of this Agreement shall be extended for one additional period of 12
months upon mutual agreement to continue. At the end of such 12 months period, this Agreement shall be extended for another additional
12 months period upon mutual agreement to continue.



 




    	 	 	Page 2 of 3



     


    

 





CytoSorbentsExclusive Distribution Agreement




 


Confidential treatment has been requested
with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.


 


IN WITNESS WHEREOF, the parties hereto
have signed this Agreement.


  


	CytoSorbents
    Europe GmbH:	 
	 	 	 
	Date
    of signature: 	December
    15, 2015           	 
	 	 	 
	By:	/s/ Dr. Christian
    Steiner	 
	 	 	 
	Name:	Dr. Christian
    Steiner	 
	 	 	 
	Title:	Managing
    Director	 
	 	 	 
	Aferetica
    s.r.l:	 
	 	 	 
	Date
    of signature:	December
    15, 2015           	 
	 	 	 
	By:	/s/ Mauro
    Atti	 
	 	 	 
	Name:	Mauro Atti	 
	 	 	 
	Title:	amministratore
    unico	 


 




    	 	 	Page 3 of 3